Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 201–300 of 999
Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells
Qin, L., Lai, Y., Zhao, R., Wei, X., Weng, J., Lai, P., Li, B., Lin, S., Wang, S., Wu, Q., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0437-8 · Cited by 114
Vitale, C., & Strati, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00849 · Cited by 112
“Undeniably, the commercial availability of CD19-directed CAR T cells is a real game-changer in the treatment landscape for aggressive B-cell NHL.”
MethodInfluentialCAR-T cell potency: from structural elements to vector backbone components
Mazinani, M., & Rahbarizadeh, F. (2022) · Biomarker Research · doi:10.1186/s40364-022-00417-w · Cited by 118
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
Haas, A. R., Golden, R. J., Litzky, L. A., Engels, B., Zhao, L., Xu, F., Taraszka, J. A., Ramones, M., Granda, B. W., Chang, W., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.006 · Cited by 109
Geyer, M. B., Rivière, I., Sénéchal, B., Wang, X., Wang, Y., Purdon, T. J., Hsu, M., Devlin, S. M., Palomba, M. L., Halton, E. F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122627 · Cited by 107
Dose–response correlation for CAR-T cells: a systematic review of clinical studies
Rotte, A., Frigault, M. J., Ansari, A., Gliner, B., Heery, C. R., & Shah, B. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005678 · Cited by 116
“LBCL 7-11 days a NR 4 (1-27) days for CRS 5 (3-93) days for neurotoxicity”
BackgroundMakita, S., Yoshimura, K., & Tobinai, K. (2017) · Cancer Science · doi:10.1111/cas.13239 · Cited by 99
Gauthier, J., & Yakoub‐Agha, I. (2017) · Current Research in Translational Medicine · doi:10.1016/j.retram.2017.08.003 · Cited by 111
Recent updates on CAR T clinical trials for multiple myeloma
Lin, Q., Zhao, J., Song, Y., & Liu, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1092-1 · Cited by 106
Development of CAR-T cell therapies for multiple myeloma
Gagelmann, N., Riecken, K., Wolschke, C., Berger, C., Ayuk, F. A., Fehse, B., & Kröger, N. (2020) · Leukemia · doi:10.1038/s41375-020-0930-x · Cited by 107
“Several immune responses against CAR-T cell therapy within a recipient, eventually limiting reducing CAR-T cell survival, have been demonstrated in clinical trials [28, 85, 86].”
BackgroundAbsence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products
Cornetta, K., Duffy, L., Turtle, C. J., Jensen, M., Forman, S., Binder-Scholl, G., Fry, T., Chew, A., Maloney, D. G., & June, C. H. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.008 · Cited by 98
Self-citationT Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
Mehta, P. H., Fiorenza, S., Koldej, R. M., Jaworowski, A., Ritchie, D. S., & Quinn, K. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780442 · Cited by 95
“The disease biology is very different between these patient groups, but NHL, MM and CLL patients also tend to be heavily pre-treated and older.”
BackgroundInfluentialLee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1026 · Cited by 105
Strategies to enhance CAR-T persistence
Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X. (2022) · Biomarker Research · doi:10.1186/s40364-022-00434-9 · Cited by 97
“This result highlights the advantage of consistent and standardized CAR-T cells and response evaluation [52, 53].”
ResultUnderstanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 115
Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
Hudecek, M., Izsvák, Z., Johnen, S., Renner, M., Thumann, G., & Ivics, Z. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1304354 · Cited by 92
“…with both CAR-modified T cells in advanced hematologic malignancies and TCR-transgenic T cells in hematologic and solid tumors (Davila et al., 2014; Kochenderfer et al., 2015; Maude et al., 2014; Morgan et al., 2006; Rapoport et al., 2015, Turtle et al., 2016a, 2016b; Turtle & Maloney, 2016).”
BackgroundMethodInfluentialChimeric Antigen Receptors: A Cell and Gene Therapy Perspective
Rivière, I., & Sadelain, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.034 · Cited by 94
Hypoxia Selectively Impairs CAR-T Cells In Vitro
Berahovich, R., Liu, X., Zhou, H., Tsadik, E., Xu, S., Golubovskaya, V., & Wu, L. (2019) · Cancers · doi:10.3390/cancers11050602 · Cited by 94
“In the clinic, a 1:1 mixture of separate CD4+ CAR-T cells and CD8+ CAR-T cells was found to be highly efficacious in adult B-ALL patients [31].”
BackgroundSignaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 110
“Nevertheless, due to the neurotoxicity of CAR-T therapy, patients with CNS involvement were excluded from clinical trials.(359) Abramson et al.”
BackgroundZhi, C., Wei, R., Ma, Q., Shi, L., He, F., Shi, Z., Jin, T., Xie, R., Wei, B., Chen, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.022 · Cited by 98
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao, Z., Chyra, Z., Kotulová, J., Celichowski, P., Mihályová, J., Charvátová, S., & Hájek, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01193-6 · Cited by 118
Modulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Chou, C. K., & Turtle, C. J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729735 · Cited by 96
Dekker, L., Calkoen, F., Jiang, Y., Blok, H., Veldkamp, S. R., de Koning, C. C. H., Spoon, M., Admiraal, R., Hoogerbrugge, P. M., Vormoor, B. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006700 · Cited by 91
Combining chemotherapy with CAR-T cell therapy in treating solid tumors
Wang, A. X., Ong, X., D’Souza, C., Neeson, P. J., & Zhu, J. J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140541 · Cited by 113
“*CORRESPONDENCE Joe Jiang Zhu joe.zhu@petermac.org †These authors share first authorship ‡These authors share senior authorship”
BackgroundDeterminants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
van de Donk, N. W. C. J., Themeli, M., & Usmani, S. Z. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0227 · Cited by 95
Yu, W.-L., & Hua, Z.-C. (2019) · Cancers · doi:10.3390/cancers11010047 · Cited by 89
Duan, D., Wang, K., Cheng, W., Feng, D., Liu, Y., He, Q., Xu, X., Wang, C., Zhao, S., Lv, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609421 · Cited by 100
Sauter, C. S., Sénéchal, B., Rivière, I., Ni, A., Bernal, Y. J., Wang, X., Purdon, T. J., Hall, M., Singh, A. N., Szenes, V., et al. (2019) · Blood · doi:10.1182/blood.2018883421 · Cited by 91
Maschan, M., Caimi, P. F., Reese-Koc, J., Sanchez, G. P., Sharma, A. A., Molostova, O., Shelikhova, L., Pershin, D., Stepanov, A., Muzalevskii, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27312-6 · Cited by 88
Perica, K., Curran, K. J., Brentjens, R. J., & Giralt, S. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.02.018 · Cited by 93
Casucci, M., Falcone, L., Camisa, B., Norelli, M., Porcellini, S., Stornaiuolo, A., Ciceri, F., Traversari, C., Bordignon, C., Bonini, C., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00507 · Cited by 94
“Over the last 5 years, different US Institutions have shown impressive antitumor effects after infusing CD19 CART cells in patients with refractory Bcell malignancies, including chronic lympho cytic leukemia (2, 3), Bcell acute lymphoblastic leukemia (4–7) and nonHodgkin lymphomas (2, 8).”
BackgroundMethodLi, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 100
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell–Associated Neurotoxicity
Mackall, C. L., & Miklos, D. B. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1084 · Cited by 91
Updates on CAR T‐cell therapy in B‐cell malignancies
Jacoby, E., Shahani, S. A., & Shah, N. N. (2019) · Immunological Reviews · doi:10.1111/imr.12774 · Cited by 86
Monitoring CAR T‐cells using flow cytometry
Demaret, J., Varlet, P., Trauet, J., Beauvais, D., Grossemy, A., Hégo, F., Yakoub‐Agha, I., & Labalette, M. (2021) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.21941 · Cited by 84
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
Gorovits, B., & Koren, E. (2019) · BioDrugs · doi:10.1007/s40259-019-00354-5 · Cited by 89
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Watanabe, N., McKenna, M. K., Shaw, A. R., & Suzuki, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.023 · Cited by 89
NF-κB in the New Era of Cancer Therapy
Eluard, B., Thiéblemont, C., & Baud, V. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.04.003 · Cited by 91
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
Tedesco, V. E., & Mohan, C. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001249 · Cited by 89
Costa, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 101
MAGE-A antigens as targets for cancer immunotherapy
Schooten, E., Maggio, A. D., Henegouwen, P. M. P. V. B. E., & Kijanka, M. M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.009 · Cited by 89
Xu, J., Wang, B., Yu, S., Chen, S., Yang, S., Liu, R., Chen, L., Hou, J., Chen, Z., Zhao, W., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01530-z · Cited by 99
“Other positive factors including good performance status, absence of extramedullary involvement and addition of fludarabine in the preconditioning chemotherapy were consistently deemed as determinants beneficial to patients’ outcomes [23, 24].”
BackgroundImmune evasion in cell-based immunotherapy: unraveling challenges and novel strategies
Li, Y.-R., Halladay, T., & Yang, L. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00998-8 · Cited by 101
“Additionally, chemotherapy has also provided a potential for lym-phodepleting conditioning in order to enhance CAR-T expansion, engraftment, reduce immunosuppressive cells, and increase anti-tumor efficacy [124–127].”
BackgroundCurrent status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Wang, Z., Guo, Y., & Han, W. (2017) · Protein & Cell · doi:10.1007/s13238-017-0400-z · Cited by 92
“This article is an open access publication P ro te in & C e ll Promising preliminary results were achieved in 29 evaluable adults withR/RB-ALLwho received 2 × 105, 2 × 106, or 2 × 107 CAR-T cells/kg in a defined 1:1 ration of CD4:CD8 composition.”
BackgroundMethodInfluentialEngineering CAR-T Cells for Improved Function Against Solid Tumors
Morgan, M. A., & Schambach, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02493 · Cited by 88
Safety and Tolerability of Adoptive Cell Therapy in Cancer
Wolf, B., Zimmermann, S., Arber, C., Irving, M. B., Trueb, L., & Coukos, G. (2019) · Drug Safety · doi:10.1007/s40264-018-0779-3 · Cited by 87
Byrne, M. T., Oluwole, O. O., Savani, B. N., Majhail, N. S., Hill, B. T., & Locke, F. L. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.06.036 · Cited by 81
“Data comparing fludarabine/ cyclophosphamide with cyclophosphamide conditioning chemotherapy showed that the latter was associated with increased CAR T cell expansion, persistence, and improved response rates, indicating that lymphodepletion is an important driver of response [46].”
BackgroundBaird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., et al. (2021) · Blood · doi:10.1182/blood.2020009432 · Cited by 79
Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology
Qi, T., McGrath, K. V., Ranganathan, R., Dotti, G., & Cao, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114421 · Cited by 86
Ormhøj, M., Scarfò, I., Cabral, M. L., Bailey, S. R., Lorrey, S., Bouffard, A. A., Castaño, A. P., Larson, R. C., Riley, L. S., Schmidts, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1337 · Cited by 88
Driving CAR T cell translation forward
Schultz, L. M., & Mackall, C. L. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2127 · Cited by 84
“Comparison of CAR T cell expansion and clinical outcomes in patients with non-Hodgkin’s lymphoma who received cyclophosphamide-based lymphodepletion demonstrated superior survival outcomes with the addition of fludarabine (8% clinical response compared to 50% clinical response) (4).”
BackgroundBauer, J., Köhler, N., Maringer, Y., Bucher, P., Bilich, T., Zwick, M., Dicks, S., Nelde, A., Dubbelaar, M. L., Scheid, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33746-3 · Cited by 82
Geyer, M. B., Rivière, I., Sénéchal, B., Wang, X., Wang, Y., Purdon, T. J., Hsu, M., Devlin, S. M., Halton, E. F., Lamanna, N., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.018 · Cited by 79
CCL21-loaded 3D hydrogels for T cell expansion and differentiation
del Río, E. P., Santos, F., Rodríguez, X. R., Martínez-Miguel, M., Roca-Pinilla, R., Arís, A., García‐Fruitós, E., Veciana, J., Spatz, J. P., Ratera, I., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120313 · Cited by 82
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
Porcellini, S., Asperti, C., Corna, S., Cicoria, E., Valtolina, V., Stornaiuolo, A., Valentinis, B., Bordignon, C., & Traversari, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00099 · Cited by 81
“The impact that the variable T cell subset composition of CAR T cell products have on clinical outcome are currently under study to identify the more effective T cell subset in term of efficacy and safety (25).”
BackgroundPerforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Ishii, K., Pouzolles, M., Chien, C. D., Erwin-Cohen, R. A., Kohler, M. E., Qin, H., Lei, H., Kuhn, S. A., Ombrello, A. K., Dulau‐Florea, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci130059 · Cited by 82
“IL-6 has been recognized as an important mediator of CRS (2, 9, 12, 14), and management of CRS with tocilizumab, an anti–IL-6 receptor monoclonal antibody (9, 10, 12), has been highly effective, leading to its FDA approval for the treatment of CAR T cell–related CRS (15).”
BackgroundTian, D., Qin, C., Dong, M., Heming, M., Zhou, L., Wang, W., Cai, S.-B., You, Y., Shang, K., Xiao, J., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00043-z · Cited by 81
“…our DNA-engineered anti-BCMA CAR-T cells, although required preconditioning chemotherapy which could allow favorable condition for CAR-T-cell proliferation (Geyer et al, 2019; Hirayama et al, 2019; Narayan et al, 2022; Turtle et al, 2016), showed prolonged ef fi cacy following only one single dose.”
Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses
Scott, E. M., Duffy, M. R., Freedman, J. D., Fisher, K. D., & Seymour, L. W. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700187 · Cited by 80
Hill, J. A., Krantz, E. M., Hay, K. A., Dasgupta, S., Stevens‐Ayers, T., Ignacio, R. B., Bar, M., Maalouf, J., Cherian, S., Chen, X., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000717 · Cited by 78
“01% CD19(1) normal B cells in blood leukocytes), (2) loss of CD19-directed CAR T cells (#10 FlapEF1a copies per microgram of DNA in 2 consecutive tests), (3) IgG , 400 mg/dL after CD19-CARTx among participants with IgG $ 400 mg/dL pre–CD19-CARTx, and (4) viral infections occurring .”
BackgroundChiorazzi, N., Chen, S., & Rai, K. R. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a035220 · Cited by 96
Li, S., Zhang, J., Wang, M., Fu, G., Li, Y., Li, P., Xiong, Z., Qin, D., Zhang, R., Tian, X., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15195 · Cited by 81
Chou, C. K., & Turtle, C. J. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0602-5 · Cited by 76
Clinical trials of CAR-T cells in China
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0535-7 · Cited by 75
Driouk, L., Gicobi, J. K., Kamihara, Y., Rutherford, K. D., Dranoff, G., Ritz, J., & Baumeister, S. H. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.580328 · Cited by 75
Jayaraman, P., Lim, R., Ng, J., & Vemuri, M. C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648472 · Cited by 86
“This CAR T-Cell Therapy for Refractory Large B-Cell Lymphoma employed a multiplex Luminex assay to measure seven different cytokines during their process development stage (Turtle et al., 2016).”
MethodOn-target restoration of a split T cell-engaging antibody for precision immunotherapy
Banaszek, A., Bumm, T. G. P., Nowotny, B., Geis, M., Jacob, K., Wölfl, M., Trebing, J., Kucka, K., Kouhestani, D., Gogishvili, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13196-0 · Cited by 77
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
Li, X., Daniyan, A. F., Lopez, A. V., Purdon, T. J., & Brentjens, R. J. (2020) · Leukemia · doi:10.1038/s41375-020-0874-1 · Cited by 76
Cytokine Release Syndrome Biology and Management
Cobb, D. A., & Lee, D. W. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000515 · Cited by 74
Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy
Zheng, Z., Li, S., Liu, M., Chen, C., Zhang, L., & Zhou, D. (2023) · Cancers · doi:10.3390/cancers15133476 · Cited by 83
Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives
Sršen, L., Janžič, L., Ihan, A., & Kopitar, A. N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1378944 · Cited by 80
Song, W., & Zhang, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108382 · Cited by 77
Taheri, F. H., Hassani, M., Sharifzadeh, Z., Behdani, M., Arashkia, A., & Abolhassani, M. (2019) · IUBMB Life · doi:10.1002/iub.2019 · Cited by 75
Cerrano, M., Ruella, M., Perales, M., Vitale, C., Faraci, D., Giaccone, L., Coscia, M., Maloy, M., Sánchez‐Escamilla, M., Elsabah, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00888 · Cited by 75
“Besides, in two studies investigating the clinical effects of antiCD19CART-cell products with defined CD4:CD8 ratio in R/R BALL (42) and NHL (73), Turtle and coworkers observed superior CAR T-cell peak levels in individuals receiving higher (i.”
BackgroundGuercio, M., Orlando, D., Cecca, S. D., Sinibaldi, M., Boffa, I., Caruso, S., Abbaszadeh, Z., Camera, A., Cembrola, B., Bovetti, K., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.231183 · Cited by 73
“12 clinical benefit was reported in HL and NHL(21, 30), highlighting the need of further optimization.”
BackgroundToward Better Understanding and Management of CAR-T Cell–Associated Toxicity
Schmidts, A., Wehrli, M., & Maus, M. V. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-061119-015600 · Cited by 72
Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges
Pang, Z., Lu, M., Zhang, Y., Gao, Y., Bai, J. J., Gu, J., Xie, L., & Wu, W. (2023) · Biomarker Research · doi:10.1186/s40364-023-00534-0 · Cited by 83
“In a clinical trial, 32 patients of non-Hodgkin B-cell lymphoma treated with CD19 CAR-T cells in a 1:1 ratio of CD8 + /CD4 + T cells exhibit long duration of CAR-T cells and have slow disease progression [152].”
BackgroundDing, L., Liang, M., Li, Y., Zeng, M., Liu, M., Ma, W., Chen, F., Li, C., Reis, R. L., Li, F., et al. (2023) · Advanced Science · doi:10.1002/advs.202302967 · Cited by 68
Advances in adult acute lymphoblastic leukemia therapy
Aldoss, I. T., & Stein, A. S. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1354372 · Cited by 70
Jain, M. D., Bachmeier, C. A., Phuoc, V. H., & Chávez, J. C. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s145039 · Cited by 79
“45,46 Peak expansion was also associated with grade 3 or higher neurologic events, but was not correlated with cytokine release syndrome 43 (Figure 1).”
Lei, W., Xie, M., Jiang, Q., Xu, N., Li, P., Liang, A., Young, K. H., & Qian, W. (2021) · Cancers · doi:10.3390/cancers13153912 · Cited by 76
“6 (8–57) China CD19 Turtle [46] 2017 CLL 24 (NR) 61 (40–73) USA CD19 Maude [47] * 2018 ALL 75 (NR) 11 (3–23) USA CD19 Jacoby [48] 2018 ALL 20 (60) 11 (5–48) Israel CD19 Santomasso [19] 2018 ALL 53 (75) NR USA CD19 Hirayama [49] 2019 FL 21 (67) 56 (51–62) USA CD19 Geyer [50] 2019 CLL/NHL 20 (70) 63 (43–75) USA CD19 Enb…”
BackgroundJain, M. D., & Davila, M. L. (2017) · Stem Cells · doi:10.1002/stem.2715 · Cited by 71
Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer
Jung, M., Yang, Y., McCloskey, J. E., Zaman, M., Vedvyas, Y., Zhang, X., Stefanova, D. I., Gray, K. D., Min, I. M., Zarnegar, R., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.08.009 · Cited by 68
“In addition, CAR T cell therapy after conditioning chemotherapy has shown a better response rate and greater CAR T cell expansion.(57,58) Therefore, we tested the combined treatment of paclitaxel and ICAM-1 CAR in an SNU-638 i.”
BackgroundNon-viral transfection technologies for next-generation therapeutic T cell engineering
Raes, L., Smedt, S. C. D., Raemdonck, K., & Braeckmans, K. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107760 · Cited by 70
The CD4/CD8 ratio of infused CD19‐CAR‐T is a prognostic factor for efficacy and toxicity
Galli, E., Bellesi, S., Pansini, I., Cesare, G. D., Iacovelli, C., Malafronte, R., Maiolo, E., Chiusolo, P., Sica, S., Sorà, F., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19117 · Cited by 77
“10 Currently, this CAR-T product is not commercially available in Italy.”
BackgroundIdecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma
Anderson, L. D. (2021) · Future Oncology · doi:10.2217/fon-2021-1090 · Cited by 72
Bishop, D. C., Xu, N., Tse, B., O’Brien, T. A., Gottlieb, D. J., Dolnikov, A., & Micklethwaite, K. P. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.007 · Cited by 63
GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy
Fernández, L., Fernández, A., Mirones, I., Escudero, A., Cardoso, L. C. D. A., Vela, M., Lanzarot, D., de Paz, R., Leivas, A., Gallardo, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02361 · Cited by 67
CAR T-cell immunotherapy of B-cell malignancy: the story so far
Halim, L., & Maher, J. F. (2020) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/2515135520927164 · Cited by 72
Saifi, O., Breen, W. G., Lester, S. C., Rule, W. G., Stish, B. J., Rosenthal, A. C., Munoz, J. L., Herchko, S. M., Murthy, H. S., Lin, Y., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.11.031 · Cited by 66
Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system
Hudecek, M., & Ivics, Z. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.06.003 · Cited by 64
Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma
Köksal, H., Dillard, P., Josefsson, S. E., Maggadottir, S. M., Pollmann, S., Fåne, A., Blaker, Y. N., Beiske, K., Huse, K., Kolstad, A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018029678 · Cited by 65
The antigen‐binding moiety in the driver's seat of CARs
Hanssens, H., Meeus, F., De Veirman, K., Breckpot, K., & Devoogdt, N. (2022) · Medicinal Research Reviews · doi:10.1002/med.21818 · Cited by 60
“In addition, by eliminating lymphoid‐derived cells, the body's ability to generate a response against the infused cells is also delayed and/or avoided, therefore increasing the depth of response to CAR‐T cell therapy and extending the persistence of infused cells.(78) The optimal preconditioning regimen has not been p…”
BackgroundTherapeutic mRNA delivery to leukocytes
Granot-Matok, Y., Kon, E., Dammes, N., Mechtinger, G., & Peer, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.032 · Cited by 61
CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions
Gill, S. I., & Brudno, J. N. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320085 · Cited by 75
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models
Donnadieu, E., Luu, M., Alb, M., Anliker, B., Arcangeli, S., Bonini, C., Angelis, B. D., Choudhary, R., Espie, D., Galy, A. H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003486 · Cited by 69
Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy
Hughes, A. D., Teachey, D. T., & Diorio, C. J. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01013-w · Cited by 76
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Balakrishnan, A., Rajan, A., Salter, A. I., Kosasih, P. L., Wu, Q. V., Voutsinas, J. M., Jensen, M. C., Plückthun, A., & Riddell, S. R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1479 · Cited by 62
Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR
Perales, M.-A., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.10.017 · Cited by 59
“CD19-specific Chimeric Antigen Receptor (CAR) T-cell immunotherapy has shown significant antitumor activity in the treatment of high-risk relapsed and refractory leukemias and lymphomas, and has revolutionized the treatment landscape for patients with advanced lymphoid malignancies [1-19].”
InfluentialChimeric antigen receptor T‐cell therapies: Optimising the dose
Dasyam, N., George, P., & Weinkove, R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14281 · Cited by 61
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.